ADMA

ADMA Biologics Inc

ADMA.US admabiologics.com
9.23
-0.16 (-1.70%)
USD · NASDAQ
52-week range
7.21
20.46
Trading at 15% of the 52-week range
Market Cap
2.07B
P/E Ratio
13.19
Forward P/E
9.33
Book Value
1.81
Div. Yield
N/A
% Institutions
93.18%
% Insiders
1.97%

1 Year

-42.7%

3 Year

+141.6%

10 Year

+63.4%
Description

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Company Information

Company Name
ADMA Biologics Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US0008991046
CIK: 0001368514
CUSIP: 000899104
Currency: USD
Full Time Employees: 640
Phone: 201 478 5552
Fiscal Year End: December
IPO Date: Oct 17, 2013
Description:

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Address:

465 State Route 17, Ramsey, NJ, United States, 07446

People

Directors & Officers

Name Title Year Born
Mr. Adam S. Grossman Co-Founder, President, CEO & Director 1977
Dr. Jerrold B. Grossman D.P.S., Ph.D. Co-Founder & Vice Chairman of the Board 1948
Mr. P. Terence Kohler CFO & Treasurer NA
Ms. Kaitlin M. Kestenberg COO & Senior VP of Compliance 1987
Mr. Michael Goldstein General Counsel NA
Mr. John Hafl Executive Director of Sales NA
Mr. Skyler Bloom Senior Director of Business Development & Corporate Strategy NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Mar 09, 2026 Kaitlin M Kestenberg-Messina N/A Sale 10.10K $15.63 $157.80K
Mar 05, 2026 Steve Elms N/A Purchase 7.00K $15.67 $109.69K
Jun 16, 2025 Steve Elms N/A Sale 194.75K $20.24 $3.94M
Jun 13, 2025 Steve Elms N/A Sale 137.93K $20.82 $2.87M
Jun 12, 2025 Steve Elms N/A Sale 92.94K $21.69 $2.02M
Jun 09, 2025 Jerrold B Grossman N/A Sale 10.00K $21.31 $213.10K
Jun 09, 2025 Lawrence P Guiheen N/A Sale 20.00K $20.96 $419.20K
May 22, 2025 Lawrence P Guiheen N/A Sale 1.22K $20.12 $24.57K
May 21, 2025 Lawrence P Guiheen N/A Sale 7.78K $20.32 $158.07K

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
BlackRock Inc 36.83M Mar 31, 2026 16.44% $0.01 1.37%
State Street Corp 14.08M Mar 31, 2026 6.29% $0.00 3.58%
Vanguard Capital Management, LLC 10.31M Mar 31, 2026 4.60% $0.00 0.00%
Vanguard Portfolio Management, LLC 8.87M Mar 31, 2026 3.96% $0.00 0.00%
Capital Research Global Investors 8.76M Jun 30, 2026 3.91% $0.01 -21.76%
First Trust Advisors L.P. 7.80M Jun 30, 2026 3.48% $0.04 2,064.90%
Nuveen, LLC 6.10M Mar 31, 2026 2.72% $0.01 2.90%
Geode Capital Management, LLC 5.82M Mar 31, 2026 2.60% $0.00 -0.12%
Caligan Partners LP 5.73M Jun 30, 2026 2.56% $2.25 20.36%
D. E. Shaw & Co LP 5.27M Jun 30, 2026 2.35% $0.02 840.50%
Amvescap Plc. 4.12M Mar 31, 2026 1.84% $0.00 -65.04%
Bank of America Corp 4.00M Mar 31, 2026 1.78% $0.00 107.53%
Dimensional Fund Advisors, Inc. 3.61M Jun 30, 2026 1.61% $0.01 -27.95%
Point72 Asset Management, L.P. 3.29M Mar 31, 2026 1.47% $0.04 734.97%
B Group, Inc 3.21M Mar 31, 2026 1.43% $21.43 30.52%
Jane Street Group LLC 3.05M Mar 31, 2026 1.36% $0.00 564.30%
The Goldman Sachs Group Inc 2.80M Mar 31, 2026 1.25% $0.00 162.13%
Morgan Stanley - Brokerage Accounts 2.43M Mar 31, 2026 1.09% $0.00 24.94%
Franklin Templeton Inc 2.34M Mar 31, 2026 1.05% $0.01 -16.07%
Northern Trust Corp 2.28M Mar 31, 2026 1.02% $0.00 0.46%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 iShares Core S&P Small-Cap ETF 14.11M 6.30% ▼ 0.16% Aug 31, 2026
2 First Trust NYSE Arca Biotech ETF 9.97M 4.45% ▲ 0.00% Aug 31, 2026
3 American Funds SMALLCAP World A 8.52M 3.81% ▼ 17.08% Jun 30, 2026
4 State Street® SPDR® S&P® Biotech ETF 8.20M 3.66% ▼ 1.06% Aug 31, 2026
5 Vanguard MStar Total Stk Mkt Idx Invest 7.05M 3.15% ▲ 0.39% Jul 31, 2026
6 iShares Russell 2000 ETF 5.90M 2.63% ▼ 0.57% Aug 31, 2026
7 Vanguard Institutional Extnd Mkt Idx Tr 2.66M 1.19% ▲ 0.17% Jul 31, 2026
8 Vanguard Small Cap Index 2.53M 1.13% ▲ 0.46% Jul 31, 2026
9 Fidelity Small Cap Index 2.50M 1.12% ▲ 8.14% Jun 30, 2026
10 iShares S&P Small-Cap 600 Growth ETF 2.20M 0.98% ▲ 0.10% Aug 28, 2026

Financial Highlights

Market Cap: $2.07B
EBITDA: $224.19M
P/E Ratio: $13.19
PEG Ratio: $0.00
Book Value: $1.81
Earnings/Share: $0.70
Profit Margin: 32.98%
Operating Margin: -123.39%
ROA (TTM): 21.78%
ROE (TTM): 41.90%
Revenue (TTM): $512.28M
Revenue/Share (TTM): $2.18
Earnings Growth (YOY): -52.80%
Revenue Growth (YOY): 15.90%

Valuation Metrics

Enterprise Value: $2.14B
Trailing P/E: 13.19
Forward P/E: 9.33

Shares Statistics

Shares Outstanding: 223.98M
Shares Float: 219.66M
% Insiders: 1.97%
% Institutions: 93.18%
Short % Float: 13.13%

Stock Price History

1 Year Price History

3 Years Price History

10 Years Price History

Financial Charts

Revenue, Net Income & Operating Cash Flow (Yearly)

Revenue, Net Income & Operating Cash Flow (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$510.17M
Cost of Goods Sold
adjust
$-217.41M
Gross Profit
subtotal
$292.77M
SG&A
adjust
$-91.58M
R&D
adjust
$-4.76M
Other Operating Expense
adjust
$-4.98M
Operating Income
subtotal
$191.44M
Other / Non-Operating Items
adjust
$-44.51M
Net Income
subtotal
$146.93M

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about ADMA.US!